... diseases that are or it expects will be in Phase 1/2 or Phase 2 clinical studies by early 2014. (5) Based in Shelton, CT , Cara Therapeutics ($CARA) scheduled a $60 million IPO on the Nasdaq with a market capitalization of $262 million at a price ...
via Shelton Newswire http://ift.tt/1b2vKuG
via Shelton Newswire http://ift.tt/1b2vKuG
No comments:
Post a Comment